Cargando…
Mapracorat, a selective glucocorticoid receptor agonist, causes apoptosis of eosinophils infiltrating the conjunctiva in late-phase experimental ocular allergy
BACKGROUND: Mapracorat, a novel nonsteroidal selective glucocorticoid receptor agonist, has been proposed for the topical treatment of inflammatory disorders as it binds with high affinity and selectivity to the human glucocorticoid receptor and displays a potent anti-inflammatory activity, but seem...
Autores principales: | Baiula, Monica, Bedini, Andrea, Baldi, Jacopo, Cavet, Megan E, Govoni, Paolo, Spampinato, Santi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061172/ https://www.ncbi.nlm.nih.gov/pubmed/24959069 http://dx.doi.org/10.2147/DDDT.S62659 |
Ejemplares similares
-
Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist
por: Baiula, Monica, et al.
Publicado: (2011) -
Anti-allergic effects of mapracorat, a novel selective glucocorticoid receptor agonist, in human conjunctival fibroblasts and epithelial cells
por: Cavet, Megan E., et al.
Publicado: (2013) -
Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells
por: Cavet, Megan E., et al.
Publicado: (2010) -
Therapeutic Targeting of Eosinophil Adhesion and Accumulation in Allergic Conjunctivitis
por: Baiula, Monica, et al.
Publicado: (2012) -
Quantitative Systems Pharmacology and Biased Agonism at Opioid Receptors: A Potential Avenue for Improved Analgesics
por: Bedini, Andrea, et al.
Publicado: (2022)